AstraZeneca plc (AZN) Rating Reiterated by HSBC
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reaffirmed by investment analysts at HSBC in a research report issued on Wednesday. They presently have a GBX 4,700 ($58.72) target price on the biopharmaceutical company’s stock. HSBC’s price target points to a potential upside of 11.64% from the stock’s current price.
Other equities analysts also recently issued research reports about the company. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 4,900 ($61.22) price objective (up previously from GBX 4,800 ($59.97)) on shares of AstraZeneca plc in a research report on Monday, August 8th. Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, August 10th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.98) price objective on AstraZeneca plc and gave the stock a “sell” rating in a research report on Wednesday, August 10th. Jefferies Group lifted their target price on AstraZeneca plc from GBX 4,800 ($59.97) to GBX 5,050 ($63.09) and gave the company a “hold” rating in a research report on Thursday, August 4th. Finally, Berenberg Bank restated a “buy” rating and issued a GBX 5,550 ($69.34) target price on shares of AstraZeneca plc in a research report on Thursday, September 8th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. AstraZeneca plc has an average rating of “Hold” and an average price target of GBX 4,969.94 ($62.09).
Shares of AstraZeneca plc (LON:AZN) opened at 4263.00 on Wednesday. The company’s market cap is GBX 53.93 billion. The company’s 50-day moving average price is GBX 4,647.09 and its 200-day moving average price is GBX 4,583.08. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.